These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Inhibition of deoxyribonucleic acid synthesis by difluoromethylornithine. Role of polyamine metabolism in monocrotaline-induced pulmonary hypertension. Hacker AD Biochem Pharmacol; 1992 Sep; 44(5):965-71. PubMed ID: 1530663 [TBL] [Abstract][Full Text] [Related]
7. Effects of endothelin-1 on vascular permeability in the conscious rat: interactions with platelet-activating factor. Filep JG; Sirois MG; Rousseau A; Fournier A; Sirois P Br J Pharmacol; 1991 Dec; 104(4):797-804. PubMed ID: 1667286 [TBL] [Abstract][Full Text] [Related]
10. [Role of leukotriene B4 in monocrotaline-induced pulmonary hypertension]. Tabata T; Ono S; Song C; Noda M; Suzuki S; Tanita T; Fujimura S Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Feb; 35(2):160-6. PubMed ID: 9103852 [TBL] [Abstract][Full Text] [Related]
11. Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model. Liu CP; Dai ZK; Huang CH; Yeh JL; Wu BN; Wu JR; Chen IJ Kaohsiung J Med Sci; 2014 Jun; 30(6):267-78. PubMed ID: 24835346 [TBL] [Abstract][Full Text] [Related]
12. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats. Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924 [TBL] [Abstract][Full Text] [Related]
13. CPU0213, a non-selective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats. Cui B; Cheng YS; Dai DZ; Li N; Zhang TT; Dai Y Clin Exp Pharmacol Physiol; 2009 Feb; 36(2):169-75. PubMed ID: 18986320 [TBL] [Abstract][Full Text] [Related]
14. 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Tofovic SP; Zhang X; Jackson EK; Dacic S; Petrusevska G Vascul Pharmacol; 2006 Dec; 45(6):358-67. PubMed ID: 16872912 [TBL] [Abstract][Full Text] [Related]
15. Bronchial and vascular effects of Paf in the rat isolated lung are completely blocked by WEB 2086, a novel specific Paf antagonist. Casals-Stenzel J; Franke J; Friedrich T; Lichey J Br J Pharmacol; 1987 Aug; 91(4):799-802. PubMed ID: 3664079 [TBL] [Abstract][Full Text] [Related]
16. Quantitative assessment of increased airway microvascular permeability to 125I-labelled plasma fibrinogen induced by platelet activating factor and bradykinin. Pedersen KE; Rigby PJ; Goldie RG Br J Pharmacol; 1991 Sep; 104(1):128-32. PubMed ID: 1664758 [TBL] [Abstract][Full Text] [Related]
17. Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline-induced endothelial apoptosis in rats. Wang Y; Zhang XH; Wang HL Can J Physiol Pharmacol; 2011 May; 89(5):345-54. PubMed ID: 21619414 [TBL] [Abstract][Full Text] [Related]
18. Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension. Vignozzi L; Morelli A; Cellai I; Filippi S; Comeglio P; Sarchielli E; Maneschi E; Vannelli GB; Adorini L; Maggi M J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):277-292. PubMed ID: 27425465 [TBL] [Abstract][Full Text] [Related]